What are Merck KGaA's updated 2026 full-year sales and EBITDA guidance ranges, and how do they compare to the previous guidance?

Merck KGaA has raised its 2026 full-year group net sales guidance to €20.4 billion–€21.4 billion, up from the prior range of €20.0 billion–€21.1 billion; it also increased its EBITDA guidance to €5.7 billion–€6.1 billion, from €5.5 billion–€6.0 billion previously. These upward revisions reflect stronger momentum in the Life Science and Healthcare segment, despite ongoing macroeconomic, geopolitical, and currency headwinds.

What impact has the Middle East conflict had on Merck KGaA’s operations and financial position as of the first quarter of 2026?

As of the first quarter of 2026, Merck KGaA stated that the Middle East conflict has had no direct material impact on its net assets, financial position, or results of operations; the region accounts for around 2% of its net sales, and the company maintains subsidiaries in Israel, Saudi Arabia, and the UAE. Indirect effects include increased logistics and energy costs, while customer payment behavior in the region is being closely monitored, with impairment losses to be recognized if necessary.

Merck Lifts 2026 Profit, Sales Outlook on Life Science, Healthcare Resilience

May 13, 2026

Merck KGaA upgraded its 2026 earnings and sales guidance driven by strong momentum in Life Science and Healthcare segments despite currency headwinds. The company cited solid demand across its portfolio while monitoring geopolitical risks affecting logistics costs.

chemweek

2025-11-13

Merck KGaA tightens guidance; Q3 earnings rise, beat estimates

2025-11-20

Merck KGaA launches supercomputer to advance innovation

2026-01-20

Merck KGaA partners with technology firm in Singapore to improve chemical R&D

2026-03-05

Merck KGaA posts decline in earnings on negative currency effects

2026-05-13

Merck Lifts 2026 Profit, Sales Outlook on Life Science, Healthcare Resilience

Merck Lifts 2026 Profit, Sales Outlook on Life Science, Healthcare Resilience

FAQ